PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product PGAs - Market size and forecast 2018-2023 Non-PGAs - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Aerie Pharmaceuticals Inc. Allergan Plc Bausch Health Companies Inc. Novartis AG Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: PGAs - Market size and forecast 2018-2023 ($ millions) Exhibit 20: PGAs - Year-over-year growth 2019-2023 (%) Exhibit 21: Non-PGAs - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Non-PGAs - Year-over-year growth 2019-2023 (%) Exhibit 23: Market opportunity by product Exhibit 24: Customer landscape Exhibit 25: Market share by geography 2018-2023 (%) Exhibit 26: Geographic comparison Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Projections for glaucoma (2010, 2030, and 2050) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Population aged 65 years and above (% of total) in Asia 2017 Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Some late-stage drugs in pipeline for open-angle glaucoma treatment Exhibit 44: Some of the combination drugs Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Aerie Pharmaceuticals Inc. - Vendor overview Exhibit 52: Aerie Pharmaceuticals Inc. - Business segments Exhibit 53: Aerie Pharmaceuticals Inc. - Organizational developments Exhibit 54: Aerie Pharmaceuticals Inc. - Key offerings Exhibit 55: Aerie Pharmaceuticals Inc. - Key customers Exhibit 56: Allergan Plc - Vendor overview Exhibit 57: Allergan Plc - Business segments Exhibit 58: Allergan Plc - Organizational developments Exhibit 59: Allergan Plc - Geographic focus Exhibit 60: Allergan Plc - Segment focus Exhibit 61: Allergan Plc - Key offerings Exhibit 62: Allergan Plc - Key customers Exhibit 63: Bausch Health Companies Inc. - Vendor overview Exhibit 64: Bausch Health Companies Inc. - Product segments Exhibit 65: Bausch Health Companies Inc. - Organizational developments Exhibit 66: Bausch Health Companies Inc. - Geographic focus Exhibit 67: Bausch Health Companies Inc. - Segment focus Exhibit 68: Bausch Health Companies Inc. - Key offerings Exhibit 69: Bausch Health Companies Inc. - Key customers Exhibit 70: Novartis AG - Vendor overview Exhibit 71: Novartis AG - Business segments Exhibit 72: Novartis AG - Organizational developments Exhibit 73: Novartis AG - Geographic focus Exhibit 74: Novartis AG - Segment focus Exhibit 75: Novartis AG - Key offerings Exhibit 76: Novartis AG - Key customers Exhibit 77: Pfizer Inc. - Vendor overview Exhibit 78: Pfizer Inc. - Business segments Exhibit 79: Pfizer Inc. - Organizational developments Exhibit 80: Pfizer Inc. - Geographic focus Exhibit 81: Pfizer Inc. - Segment focus Exhibit 82: Pfizer Inc. - Key offerings Exhibit 83: Pfizer Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.